

Diabetes 2030 Forecasts, 2015

WASHINGTON, DC Metropolitan Area Diabetes Data & Forecasts

Includes: Washington-Arlington-Alexandria, DC-VA-MD-WV Metropolitan Statistical Area

Metro Total Population Forecasts	2015	2020	2025	2030
Entire Population	5,822,200	6,163,000	6,514,400	6,668,900
Prediabetes	1,509,800	1,650,800	1,797,200	1,842,300
Diagnosed diabetes	356,900	447,500	531,800	587,800
Undiagnosed diabetes	164,100	195,400	220,300	230,800
Total with diabetes (diagnosed and undiagnosed)	521,000	642,900	752,100	818,600
Complications:				
Visual impairment	58,500	71,200	82,200	88,200
Renal failure	850	1,030	1,180	1,260
Leg amputations	740	850	930	950
Annual deaths attributable to diabetes	3,840	4,600	5,190	5,430
Total annual cost (2015 dollars)	\$6.6 B	\$8.1 B	\$9.5 B	\$10.3 B
Annual medical costs	\$4.8 B	\$5.8 B	\$6.8 B	\$7.4 B
Annual nonmedical costs	\$1.8 B	\$2.3 B	\$2.7 B	\$2.9 B

Metro Senior Population Forecasts	2015	2020	2025	2030
Population 65 and older	697,200	767,300	842,000	893,600
Prediabetes	355,600	391,300	429,400	455,800
Diagnosed diabetes	131,800	145,000	159,100	168,900
Undiagnosed diabetes	48,800	53,700	58,900	62,600
Total with diabetes (diagnosed and undiagnosed)	180,600	198,700	218,100	231,500
Complications:				
Visual impairment	24,700	26,400	28,300	29,200
Renal failure	410	430	460	470
Leg amputations	300	310	310	310
Annual deaths attributable to diabetes	2,650	3,080	3,370	3,420
Total annual cost (2015 dollars)	\$2.3 B	\$2.5 B	\$2.8 B	\$3.0 B
Annual medical costs	\$2.2 B	\$2.4 B	\$2.6 B	\$2.8 B
Annual nonmedical costs	\$0.1 B	\$0.1 B	\$0.2 B	\$0.2 B

These forecasts are based on the latest available national diabetes data, including U.S. Census Bureau population projections, the CDC National Diabetes Statistics Report, 2014, CDC diabetes morbidity trend reports, CDC's latest diabetes prevalence projections to 2050 and Dall, et al. "The Economic Burden of Elevated Blood Glucose Levels in 2012: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes," *Diabetes Care* 2014;37:3172-3179. These forecasts assume a steady, but conservative, reduction in the number of people with complications due to better awareness of the risks of diabetes, earlier screening and intervention, and more effective therapies.

For details and references on the Institute for Alternative Futures Diabetes 2030 Forecasting Model Methodology, visit www.altfutures.org/diabetes2030.

Research funded by Novo Nordisk Inc.